xmt-1660
xmt-1660: sourced relationships with 1 company · 1 clinical trial tracked.
xmt-1660 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could xmt-1660 → MRSN affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Mersana Therapeutics, Inc. (MRSN) | Phase 1 |
Clinical Trial Registry Records (1)
A Phase 1, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants With Solid Tumors
Primary endpoint: Frequency of adverse events that are considered dose-limiting toxicities (DLTs) and associated with XMT-1660 during the first cycle of treatment (Dose Escalation)
Frequently asked questions
Which companies have sourced relationships with xmt-1660?
xmt-1660 has dated SEC/FDA relationship records for Mersana Therapeutics, Inc..
How many clinical trials involve xmt-1660?
BioSniper tracks 1 clinical trial involving xmt-1660.